Norwich Drug Patent Portfolio
Norwich's Family Patents
Recent FDA approvals and tentative approvals for Norwich
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Rifaximin |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 10 Jan, 2025 |
| Rifaximin |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 20 Jun, 2024 |
Clinical Trials
Recent Clinical Trials by Norwich:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Poly-unsaturated Fats for Improving Nasal Polyps and Asthma | Norfolk and Norwich University Hospitals NHS Foundation Trust | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List